Educational content only. Not medical, legal, or reimbursement advice. Coverage rules vary by state, insurer, and plan type.

Summary

• What is changing: More states are passing or expanding infertility and IVF coverage rules, but the details vary widely.
• What that can mean: In places with broader coverage, IVF cycle volume often rises.
• Why planning matters: More volume increases pressure on staffing, scheduling, paperwork, and specimen tracking.
• The main point: Planning for growth should focus on safe scaling. That means capacity plus strong traceability.

Key takeaways

• Demand can rise unevenly depending on insurance type, but the lab still feels the impact.
• Risk often increases during handoffs, such as labeling, dish and tube changes, cryostorage moves, and selection before thaw or transfer.
• Studies on electronic witnessing and scanning-based checks show time savings and traceability process benefits when implemented well.

What is changing in fertility coverage

Across the U.S., infertility coverage laws are expanding and evolving, but what coverage includes still varies by state and by plan type. Some laws require insurers to cover certain services. Others require insurers to offer coverage options that employers may or may not choose.

One detail affects how demand shows up at clinics. State insurance rules often do not apply to self-insured employer plans because of federal law. That means access may expand quickly for some people in a state while others in the same area see little change. This can create uneven scheduling pressure. Even if coverage expands in only part of the market, the lab still sees the downstream impact. That can mean more cycles to coordinate, more specimens to track, and more identity checks under time pressure.

What research suggests about growing demand

When fertility coverage becomes broader, IVF cycle volume tends to increase at a population level.

One analysis using 2018 CDC ART reporting data found IVF cycle rates were notably higher in states the authors grouped as having more comprehensive IVF insurance mandates, compared with states without comprehensive mandates. Claims-based research also suggests spending on infertility treatment is higher in mandate states, especially among fully insured plans that are most directly affected by state rules.

Important note: This does not mean every clinic will experience the same increase. But it supports a reasonable planning assumption. Coverage expansion can drive meaningful growth in demand, enough to stretch workflows and raise risk if systems do not scale reliably.

Why higher volume can increase risk

In IVF labs, the most serious failures are often not about technical skill. They are about identity and traceability. That means the right specimen, for the right patient, at the right step, every time.

As workflows add steps, such as more cryopreservation and more handling, the number of times staff must verify identity increases. Each verification point is also a moment where interruptions, fatigue, or routine can create risk, especially when teams are trying to keep up with higher volume.

This is why many lab quality frameworks treat identification and traceability as core requirements. Good-practice lab guidance emphasizes strong systems for unique identification and traceability of reproductive cells and related records as part of quality management.

What end-to-end traceability means

End-to-end traceability means a clinic can clearly answer:

• What specimen was handled
• Who handled it
• When it happened
• Where it happened, including workstation and cryostorage location
• How it was verified, including witnessing and verification steps

In practice, that usually requires:

• A consistent labeling and ID approach that stays with a specimen through all steps
• A record of key verification moments captured at the time work is done
• A clear storage location system and a reliable movement log
• Auditability, so issues can be investigated and improvements made

What studies say about electronic witnessing

Electronic witnessing and scanning-based verification systems are often discussed because they can reduce reliance on memory and manual transcription while creating an audit-ready record of key steps.

A prospective study comparing manual versus electronic witnessing reported that electronic witnessing reduced the time needed for witnessing steps and was viewed positively by embryologists for traceability and fewer workflow disruptions. A separate long-run evaluation over 10 years described how electronic witnessing systems capture mismatch events and other exceptions. That can help teams find near-misses and improve processes.

What research does not claim:

Technology alone does not remove the need for training and good procedure design. Implementation matters, and systems can introduce new considerations that must be managed.

Where clinics feel pressure first

Staffing and scheduling

Higher demand can compress time windows for critical lab tasks. Good-practice guidance emphasizes that staffing should reflect workload and procedure complexity, not just annual cycle count.

What helps

• Forecast demand as workload units, not just cycles. For example, retrievals, transfers, vitrification and warming events, and biopsy-related steps.
• Protect time for high-focus tasks by reducing interruptions during critical steps.

Documentation and records

As identity checks increase, manual documentation can become harder to complete reliably and on time, especially when staff are interrupted mid-task.

What helps

• Identify where documentation gets duplicated or corrected later. That can be a sign the process is stretched.
• Standardize what must be recorded at the time the work occurs, versus what can be added later.

Cryostorage tracking

More cycles often means more cryopreserved embryos and gametes, stored longer. That increases the importance of accurate location tracking and safe movement logs.

Some programs also plan for offsite cryostorage. This can help when on-site space is limited or when long-term storage volume grows quickly. It can also support continuity during renovations, expansions, or emergencies. Offsite storage adds extra handoffs, so it only works well when the clinic and the storage site follow clear written steps for identification, transport, receiving, and documentation.

What helps

• Review storage capacity early and often. Track how many new specimens are added each month and how many are removed for warming or transfer. This helps you estimate when you will need more space or more tanks.

• Keep a clear storage map and naming convention so staff can quickly confirm where each specimen is located.

• Use a consistent process for logging every movement. That includes moves within a tank, moves between tanks, and moves between sites.

• If offsite storage is used, set written steps for shipping and receiving. Include who checks identifiers, what paperwork travels with the shipment, how the receiving site confirms what arrived, and how the final storage location is recorded.

• Make sure alarms are monitored at all times and that there is a clear response plan if a tank alarm triggers.

• Do regular checks to confirm the records match what is stored. If there is a mismatch, have a documented process for reconciling it safely.

Digitization of cryostorage management

Strong manual processes are the foundation of safe cryostorage. Many clinics are also adding digital tools to support those processes. Examples include machine-readable identifiers such as barcodes or RFID, clearer location mapping, and real-time inventory tracking. When used well, these tools can reduce reliance on handwritten logs and repeated manual checks, improve traceability, and support a more reliable chain of custody for cryopreserved specimens across both on-site and off-site storage.

Ongoing improvement and near-miss review

High-reliability systems improve by learning from near-misses, not just adverse events. Long-run evaluations show mismatch and exception events can be tracked and reviewed to strengthen processes over time.

What helps

• Define a short list of near-miss categories, such as mismatch alerts, mislabeling caught early, and location discrepancies.
• Review patterns regularly to fix system weaknesses, not to assign blame.

Case study: California SB 729 and why it matters for planning

California SB 729 is an example of how state policy can expand infertility coverage requirements, including IVF, and broaden the definition of infertility in an inclusive way.

In enacted text, SB 729 sets coverage requirements for certain large group plans and policies and requires small group plans and policies to offer such coverage. It also defines infertility to include a person’s inability to reproduce as an individual or with their partner without medical intervention, alongside clinical and time-based definitions.

Why this matters for clinic operations:

When coverage expands in a large market, demand can increase. Policy timelines can create a window to stress-test capacity and specimen tracking workflows.

A careful comparison from other healthcare settings

Other parts of healthcare have used standardized identification and scanning to reduce manual processes and improve traceability. A widely cited example is the NHS Scan4Safety program in the U.K., which reports operational benefits and stronger traceability processes after adopting GS1 standards.

The point is simple. In complex environments, standardized identification and consistent checks can reduce reliance on memory and manual transcription.

Bottom line

Expanded coverage can be a meaningful access shift for patients. For clinics, it also changes the operating environment. That can mean higher volume, more steps, more specimens in storage, and more identity checks.

Planning for demand growth cannot be capacity alone. It should also include the systems and habits that help a lab stay reliable, especially around specimen identification, verification, and cryostorage tracking.

__________ 

Appendix A: Evidence and sources for review

Fast claim-to-source map

• State coverage landscape varies by state and plan type: Sources 1 to 2
• Self-insured plans often exempt from state mandates, which can make demand uneven: Sources 2 and 4
• More comprehensive mandates are linked with higher IVF cycle volume: Source 3
• Mandate states show higher infertility-treatment expenditures, especially fully insured: Source 4
• Identification and traceability are core lab quality expectations: Source 5
• Electronic witnessing evidence includes efficiency and staff-perceived traceability benefits: Source 7
• Electronic witnessing can capture mismatch and exception events over time: Source 8
• Cryostorage growth and shipping controls, including the need for written procedures and verification steps: Sources 11 to 13
• Digital systems such as barcodes or RFID and electronic witnessing can support traceability and reduce reliance on manual documentation: Sources 5, 7, 8, and 12
• SB 729 details: Source 9
• Scan4Safety comparison: Source 10
• Pettit quote and workflow risk framing: Source 6

Full sources

Source 1: RESOLVE: The National Infertility Association. (n.d.). Insurance coverage by state. Retrieved April 21, 2026, from https://resolve.org/learn/financial-resources/insurance-coverage/insurance-coverage-by-state/ (https://resolve.org/learn/financial-resources/insurance-coverage/insurance-coverage-by-state/)

Source 2: Kaiser Family Foundation. (2025). Mandated coverage of infertility treatment (State Health Facts; timeframe: as of November 2025). https://www.kff.org/state-health-policy-data/state-indicator/infertility-coverage/ (https://www.kff.org/state-health-policy-data/state-indicator/infertility-coverage/)

Source 3: Peipert, B. J., Chung, E. H., Harris, B. S., Warren, C. M., & Jain, T. (2022). Impact of comprehensive state insurance mandates on in vitro fertilization utilization, embryo transfer practices, and outcomes in the United States. American Journal of Obstetrics and Gynecology, 227(1), 64.e1 to 64.e8. https://www.ajog.org/article/S0002-9378(22)00175-2/fulltext (https://www.ajog.org/article/S0002-9378(22)00175-2/fulltext)

Source 4: Boulet, S. L., Kawwass, J., Session, D., Jamieson, D. J., Kissin, D. M., & Grosse, S. D. (2019). US state-level infertility insurance mandates and health plan expenditures on infertility treatments. Maternal and Child Health Journal, 23(5), 623 to 632. https://pmc.ncbi.nlm.nih.gov/articles/PMC11056963/ (https://pmc.ncbi.nlm.nih.gov/articles/PMC11056963/)

Source 5: European Society of Human Reproduction and Embryology. (2015). Revised guidelines for good practice in IVF laboratories (2015). https://www.eshre.eu/-/media/sitecore-files/Guidelines/IVF-lab/ESHRE_IVF_labs_guideline_15122015_FINAL.pdf (https://www.eshre.eu/-/media/sitecore-files/Guidelines/IVF-lab/ESHRE_IVF_labs_guideline_15122015_FINAL.pdf)

Source 6: Pettit, M. (2026, April 15). Why IVF must move beyond manual practice to prevent preventable errors. Unpublished manuscript. IMT Matcher.

Source 7: Holmes, R., Wirka, K. A., Catherino, A. B., Hayward, B., & Swain, J. E. (2021). Comparison of electronic versus manual witnessing of procedures within the in vitro fertilization laboratory: Impact on timing and efficiency. F and S Reports, 2(2), 181 to 188. https://pubmed.ncbi.nlm.nih.gov/34278352/ (https://pubmed.ncbi.nlm.nih.gov/34278352/)

Source 8: Sterckx, J., Wouters, K., Mateizel, I., Segers, I., De Vos, A., Van Landuyt, L., Van de Velde, H., Tournaye, H., & De Munck, N. (2023). Electronic witnessing in the medically assisted reproduction laboratory: Insights and considerations after 10 years of use. Human Reproduction, 38(8), 1529 to 1537. https://academic.oup.com/humrep/article/38/8/1529/7193345 (https://academic.oup.com/humrep/article/38/8/1529/7193345)

Source 9: California Legislature. (2024). Senate Bill No. 729 (Chapter 930): Health care coverage: Treatment for infertility and fertility services. Bill text PDF. https://www.calhealthplans.org/wp-content/uploads/2024/11/SB-729-Text.pdf (https://www.calhealthplans.org/wp-content/uploads/2024/11/SB-729-Text.pdf)

Source 10: GS1 UK. (2020, July). Scan4Safety report. Program highlights page. https://healthcare.gs1uk.org/scan4safety/ (https://healthcare.gs1uk.org/scan4safety/)

Source 11: American Society for Reproductive Medicine. (2020). Cryostorage of reproductive tissues in the in vitro fertilization laboratory: A committee opinion. Fertility and Sterility, 114, 486 to 491. https://www.asrm.org/practice-guidance/practice-committee-documents/cryostorage-of-reproductive-tissues-in-the-in-vitro-fertilization-laboratory-a-committee-opinion-2020/

Source 12: Practice Committees of the American Society for Reproductive Medicine and the Society for Reproductive Biologists and Technologists. (2022). Comprehensive guidance for human embryology, andrology, and endocrinology laboratories: Management and operations. Fertility and Sterility, 117(6), 1183 to 1202. https://integration.reproductivefacts.org/globalassets/_asrm/practice-guidance/practice-guidelines/pdf/revised_guidelines_for_human_embryology_and_andrology_laboratories.pdf

Source 13: Rinehart, L. A. (2021). Storage, transport, and disposition of gametes and embryos: Legal issues and practical considerations. Fertility and Sterility, 115(2), 274 to 281. https://www.fertstert.org/article/S0015-0282(20)32693-5/fulltext